<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>Cancer Network Newsletter</title><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#295AA6;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#295AA6;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1027" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body bgcolor="#F0F1F2" lang=EN-CA link="#295AA6" vlink="#295AA6"><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Below are several interesting articles relating to PCa.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Cancer Network [mailto:cancernetwork@email.cmpmedica-usa.com] <br><br><b>Subject:</b> ASCO: 18 Month ADT Enough in High-Risk Prostate Cancer?<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><div><p class=MsoNormal><span style='font-size:1.0pt'>Plus: Does ERG expression predict docetaxel benefit in prostate cancer?<o:p></o:p></span></p></div><div id=wrapper><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center'><span style='font-size:7.5pt;font-family:"Arial","sans-serif";color:#333333'>To view this email as a web page, click <a href="http://view.email.cmpmedica-usa.com/?qs=3ee1ff0f72e132cc79b74766b2cb9c40380137b774511cf65baf10257174b6c3edad2faf41228340535578523abb9137954b9d2e65b9fd9507c75d13708c87045757ea4aea27980f"><b><span style='font-size:8.5pt;color:#056C9C'>here.</span></b></a></span><o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#333333;border-spacing: 0'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:#333333;border-collapse:collapse'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><img border=0 width=220 id=networkLogo src="http://www.ubmmedica.com/wp-content/uploads/2016/11/ModernMedicineNetwork-small.png" alt="Modern Medicine Network"><o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2f65821b0b2641ceda490016d08194cad3da8faf554b2d8c90e4e22a3d9308ac10743cc447ff6f313"><span style='text-decoration:none'><img border=0 width=360 id=logo src="http://images.ubmmedica.com/newsletters/Logos/CancerNetworkLogo.png" alt="Cancer Network"></span></a><o:p></o:p></p></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:#1A357D;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr><td style='padding:7.5pt 7.5pt 7.5pt 7.5pt'><p class=MsoNormal><span style='font-size:9.5pt;font-family:"Arial","sans-serif";color:white'>ASCO 2017 | June 7, 2017 <o:p></o:p></span></p></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=270 style='width:202.5pt;border-collapse:collapse;border-spacing: 0' id=articles><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a27f94e5e1a5821529179b4cb147bdfd8e2f0ee0e6420557ab0fb4a966688010394568db50f2ad3389"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Prostate Cancer Highlights From ASCO 2017</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><em><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Cancer Network</span></em><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'> presents exclusive coverage on prostate cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6. We bring you expert interviews and reports on the latest trials and scientific advances that are changing the way this malignancy is managed and treated. <o:p></o:p></span></p></td></tr><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Reducing ADT to 18 Months May Be Sufficient in High-Risk Prostate Cancer</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Androgen deprivation therapy can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to results of a phase III trial. <o:p></o:p></span></p></td></tr><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a25cfd3c224af225d259d7ebf68686ce63a7ec0465b6f888e205d3cd4e094d9f65fb054bbb0da5ecd4"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 align=right width=300 style='width:225.0pt;border-collapse:collapse;border:none;margin-top:2.75pt;margin-bottom:2.75pt'><tr><td style='border:none;border-left:solid #F0F1F2 1.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:8.5pt;font-family:"Arial","sans-serif";color:#333333'>ADVERTISEMENT <o:p></o:p></span></p></td></tr><tr><td style='border:none;border-left:solid #F0F1F2 1.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><b><span style='font-size:14.5pt;font-family:"Arial","sans-serif";color:#575452'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab"></a></span></b><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
<v:stroke joinstyle="miter" />
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0" />
<v:f eqn="sum @0 1 0" />
<v:f eqn="sum 0 0 @1" />
<v:f eqn="prod @2 1 2" />
<v:f eqn="prod @3 21600 pixelWidth" />
<v:f eqn="prod @3 21600 pixelHeight" />
<v:f eqn="sum @0 0 1" />
<v:f eqn="prod @6 1 2" />
<v:f eqn="prod @7 21600 pixelWidth" />
<v:f eqn="sum @8 21600 0" />
<v:f eqn="prod @7 21600 pixelHeight" />
<v:f eqn="sum @10 21600 0" />
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect" />
<o:lock v:ext="edit" aspectratio="t" />
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" alt="" href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab" style='position:absolute;margin-left:173.8pt;margin-top:0;width:225pt;height:187.5pt;z-index:251658240;mso-wrap-distance-left:3pt;mso-wrap-distance-top:3pt;mso-wrap-distance-right:3pt;mso-wrap-distance-bottom:3pt;mso-position-horizontal:right;mso-position-horizontal-relative:text;mso-position-vertical-relative:line' o:allowoverlap="f" o:button="t">
<v:imagedata src="http://oascnx15005.247realmedia.com/RealMedia/ads/adstream_nx.ads/cancernetworkEnews/CN/Econf/06072017/106072017@x31?_RM_NX_ID_=106072017" />
<w:wrap type="square"/>
</v:shape><![endif]--><![if !vml]><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab"><img border=0 width=300 height=250 src="http://oascnx15005.247realmedia.com/RealMedia/ads/adstream_nx.ads/cancernetworkEnews/CN/Econf/06072017/106072017@x31?_RM_NX_ID_=106072017" align=right hspace=4 vspace=4 v:shapes="_x0000_s1026"></a><![endif]><b><span style='font-size:14.5pt;font-family:"Arial","sans-serif";color:#575452'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2ab8faa8e161cc31ef60db594b4a877b31f2986df8f1d3ea621a37bc0450bf75a212ac6a215b902ab"><span style='text-decoration:none'><img border=0 width=1 height=1 id="_x0000_i1027" src="https://ad.doubleclick.net/ddm/ad/N6246.131798.CANCERNETWORK/B10763357.144002873;sz=1x1;ord=12345678;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=?" alt=Advertisement></span></a></span></b><b><span style='font-size:14.5pt;font-family:"Arial","sans-serif";color:#575452'><o:p></o:p></span></b></p></td></tr></table></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33cff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?</span></b></a> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials. <o:p></o:p></span></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2c747cef284d734a33cff03f317e39ae4d739cea04758ef43d2620c6b28b7738370c976c136c4d83b"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Signature for Aggressive-Variant CRPC Predicts Platinum Sensitivity</span></b></a> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>A molecular signature for aggressive-variant prostate carcinoma can predict which men with castrate-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin. <o:p></o:p></span></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a227e63b26bb24f4fd1c05797f61e2c6285c3d4ab528f866f2120f07ecfa09801a785e37fca326bb31"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr style='height:1.5pt'><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Post-Progression Enzalutamide/Abiraterone Not Effective in Metastatic CRPC</span></b></a> <o:p></o:p></p></td></tr><tr><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Continued enzalutamide with abiraterone failed to improve PFS in men with metastatic castration-resistant prostate cancer who progressed on enzalutamide alone. <o:p></o:p></span></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a211aa6705df2ada895f588b087f5a861a838e687713285c1dbb355256fb04fab52e4ae9419f3bf1f6"><span style='font-family:"Arial","sans-serif";color:#056C9C'> Read more </span></a> <o:p></o:p></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0'><tr><td style='background:#1F7887;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal align=center style='text-align:center'><span style='font-size:15.0pt;font-family:"Arial","sans-serif";color:white'>IN CASE YOU MISSED IT <o:p></o:p></span></p></td></tr></table></div></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac678ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>Abiraterone/ADT Combo Increased Prostate Cancer Survival</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;max-width:90px'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;border-spacing: 0' id=articles><tr><td width=90 valign=top style='width:67.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><img border=0 width=70 id="_x0000_i1028" src="http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/public/fizazi-100.jpg" alt="image description here"><o:p></o:p></p></td><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Combined therapy with abiraterone acetate/prednisone plus ADT significantly improved overall survival and radiographic progression-free survival among men with metastatic hormone-naive prostate cancer.<br><br></span><span style='font-size:12.5pt;font-family:"Arial","sans-serif";color:#333333'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a240bcdbb022c83efac678ebcab86a9727e27e0427241c130ffb671cc12403b97cebb1e33225734290"><span style='color:#056C9C'> Read more </span></a></span><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse;border-spacing: 0'><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4dd4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753"><b><span style='font-size:14.0pt;font-family:"Arial","sans-serif";color:#056C9C'>STAMPEDE: Abiraterone Slowed Progression of Advanced Prostate Cancer</span></b></a> <o:p></o:p></p></td></tr><tr><td style='padding:3.75pt 3.75pt 3.75pt 3.75pt;max-width:90px'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;border-spacing: 0' id=articles><tr><td width=90 valign=top style='width:67.5pt;padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><img border=0 width=70 id="_x0000_i1029" src="http://www.cancernetwork.com/sites/default/files/styles/thumbnail_autocrop/public/james-100.jpg" alt="image description here"><o:p></o:p></p></td><td valign=top style='padding:3.75pt 3.75pt 3.75pt 3.75pt'><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'>Abiraterone at the start of ADT for men with metastatic prostate cancer significantly improved overall survival and failure-free survival, with manageable toxicity.<br><br></span><span style='font-size:12.5pt;font-family:"Arial","sans-serif";color:#333333'><a href="http://click.email.cmpmedica-usa.com/?qs=3c25bc924da5c8a2e80d5815606c963f4dd4632f698ebb570601c05d6b66c1ae2dc7b8ec4c1dc67a366b20ca15ae2753"><span style='color:#056C9C'> Read more </span></a></span><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#333333'> <o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></div><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;background:white;border-collapse:collapse;border-spacing: 0;min-width: 600px'><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'> <o:p></o:p></p></td></tr></table></div></td></tr></table><p class=MsoNormal style='background:#F0F1F2'><o:p> </o:p></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#323232'><tr><td style='padding:0cm 0cm 0cm 0cm'></td></tr><tr><td style='padding:0cm 0cm 0cm 0cm'></td></tr><tr style='height:1.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:1.5pt'><p class=MsoNormal style='mso-line-height-alt:1.5pt'><span style='font-size:7.5pt;font-family:"Arial","sans-serif"'> <o:p></o:p></span></p></td></tr></table></div></div><p class=MsoNormal><img border=0 width=1 height=1 id="_x0000_i1035" src="http://click.email.cmpmedica-usa.com/open.aspx?ffcb10-fe6716797766077f7114-fdbb1570736204787d10767d6c-feca15707d60027f-fe98157571670c7d77-fdf01575716504757d12757c-ffcf14"><o:p></o:p></p></div></body></html>